Product Information
MOMETASONE FUROATE 50 MCG SPRY is a generic product labeled by Aurobindo Pharma Limited, priced at $1.5873 per GM under NDC 59651040217. Its NADAC has been published 113 times since Aug 7, 2024.
FDA first approved this application on Mar 18, 2024. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
50 ug/1
Manufacturer
Aurobindo Pharma LimitedNDC
59651040217
Classification
Generic
Dosage Form
SPRAY, METERED
Route
NASAL
Effective Date
9/23/2026
Active Ingredients
MOMETASONE FUROATE MONOHYDRATEApproval Type
Generic (ANDA)
FDA Application
ANDA215878FDA Approved
3/18/2024
TE Code
AB
On Market Since
3/18/2024
Pharmacological Classes
Price Statistics
The NADAC for MOMETASONE FUROATE 50 MCG SPRY has been published 113 times since Aug 7, 2024, and over the history we have for it it has declined 27.2%. The table below summarizes its recorded NADAC range and movement.
| Current price | $1.5873 per GM |
|---|---|
| All-time high | $2.1803 (Aug 14, 2024) |
| All-time low | $1.5873 (Sep 23, 2026) |
| 52-week high | $1.7874 |
| 52-week low | $1.5873 |
| Median price | $1.7289 |
| Average price | $1.7433 |
| Largest weekly change | -14.3% (Nov 20, 2024) |
| Weeks tracked | 113 |
| Tracking since | Aug 7, 2024 |
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the MOMETASONE FUROATE MONOHYDRATE market page.
Lowest-Cost Alternatives
No alternatives available
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Aurobindo Pharma Limited manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
MOMETASONE FUROATE MONOHYDRATE market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Corticosteroid class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of MOMETASONE FUROATE 50 MCG SPRY?
The current National Average Drug Acquisition Cost (NADAC) for MOMETASONE FUROATE 50 MCG SPRY, manufactured by Aurobindo Pharma Limited, is $1.5873 per GM (NDC 59651040217), effective Sep 30, 2026.
How has the price of MOMETASONE FUROATE 50 MCG SPRY changed over time?
Over the history we have for it, the NADAC for MOMETASONE FUROATE 50 MCG SPRY has declined 27.2%. It has been tracked across 113 weekly CMS publications since Aug 7, 2024.
What are the highest and lowest recorded NADAC prices for MOMETASONE FUROATE 50 MCG SPRY?
Since Aug 7, 2024, the NADAC for MOMETASONE FUROATE 50 MCG SPRY has ranged from a low of $1.5873 (Sep 23, 2026) to a high of $2.1803 (Aug 14, 2024), with a median of $1.7289 per GM.
Are there cheaper alternatives to MOMETASONE FUROATE 50 MCG SPRY?
No other NADAC-published product currently shares the active ingredient and strength of MOMETASONE FUROATE 50 MCG SPRY in a comparable dosage form, so no direct lower-cost alternative is listed.
Who manufactures MOMETASONE FUROATE 50 MCG SPRY?
MOMETASONE FUROATE 50 MCG SPRY (NDC 59651040217) is labeled by Aurobindo Pharma Limited, and CMS classifies it as a generic product.